

**Table 3 Sensitivity analysis excluding cases and controls with a diagnosis of gout prior to the index date**

<b>Bisphosphonate</b>	<b>Pseudogout cases n (%)</b>	<b>Controls n (%)</b>	<b>Unadjusted IRR (95% CI)</b>	<b>Adjusted IRR (95%CI) *</b>
Any	115 (7.0)	287 (3.8)	1.84 (1.45, 2.33)	1.43 (1.11, 1.85)
Alendronic acid	82 (5.0)	200 (2.6)	1.87 (1.42, 2.47)	1.53 (1.15, 2.06)
Disodium etidronate	11 (0.7)	21 (0.3)	2.37 (1.12, 5.02)	1.56 (0.70, 3.46)
Ibandronic acid	3 (0.2)	19 (0.3)	0.68 (0.20, 2.34)	0.48 (0.13, 1.74)
Risedronate sodium	17 (1.0)	49 (0.7)	1.43 (0.80, 2.53)	1.09 (0.59, 2.00)
Sodium clodronate	2 (0.1)	1 (<0.1)	8.00 (0.73, 88.23)	1.65 (0.11, 24.91)
Tiludronate disodium	0 (0.0)	0 (0.0)	-	-

CI, confidence interval; IRR, incidence rate ratio

\* adjusted for hyperparathyroidism, osteoarthritis, rheumatoid arthritis, and prescriptions for diuretics and oral corticosteroids